Happy weekend, investors! Welcome back to Weekly Buzz where we talk about the top ten buzzing stocks on moomoo this week! Comment below to answer the Weekly Topic question for a chance to win an award!
Make Your Choice
Weekly Buzz
The market overall advanced on Friday. The news followed Nvidia's earnings on Wednesday night and Bitcoin's all-time highs.
Just past the Friday close at 4 pm ET, the     $S&P 500 Index (.SPX.US)$ traded...

$BTC Digital (BTCT.US)$ im curious what you all think. predict BTC to be at $100K+ by end of the month. id like to see what this stock does by that time. seems like its very hyped up and inflated at the moment

The SEC’s approval of options trading on $iShares Bitcoin Trust (IBIT.US)$ is more than just a headline—it’s a goldmine of opportunity for savvy investors. With Bitcoin's legendary volatility now married to the precision of options, we can play the game smarter, not riskier. Let’s explore some standout strategies in a fun and engaging way.
1. Selling Covered Calls: Turn Your ETF into a Payday
Got $iShares Bitcoin Trust (IBIT.US)$ shares or $Bitcoin (BTC.CC)$ sitting i...

$Bitcoin (BTC.CC)$'s march to a fresh all-time fueled increased interest in stocks linked to the cryptocurrency, spurring heavier options trading.
The largest cryptocurrency advanced to a new all-time high as $94,057 in New York Friday afternoon amid a surge demand from buyers including $MicroStrategy (MSTR.US)$ and issuers of exchange traded funds. The software company whose business strategy includes buying and holdi...

$Tesla (TSLA.US)$stock gained nearly 9% on Monday, sending shares to their highest level since early 2022 and giving the company a market cap north of $1.1 trillion. Since Donald Trump’s presidential triumph on Nov. 5, the electric car maker has advanced over 39%.
Tesla options draw 'euphoric' trading
Tesla's contracts were the most heavily traded options on individual stocks on Monday, with some 2.5 million contracts c...

$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...

$Advanced Micro Devices (AMD.US)$ almost there to finding nemo